NCT06996704View on ClinicalTrials.gov

A Clinical Study of AK0610

PHASE1RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions
Healthy Volunteer Study
Interventions
DRUG

AK0610 Injection solution

Active Substance: AK0610 Pharmaceutical Form: Injection solution Route of Administration: Intramuscular injection or intravenous injection.

DRUG

Placebo

Active Substance: Placebo Pharmaceutical Form: Injection Route of Administration: Intramuscular injection or intravenous injection

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital ）, Jinan

All Listed Sponsors
lead

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY